Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents
Brilliant N. Marak, Jayanta Dowarah, Laldingluaia Khiangte, et al.
European Journal of Medicinal Chemistry (2020) Vol. 203, pp. 112571-112571
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Hedgehog Signaling and Truncated GLI1 in Cancer
Daniel Doheny, Sara G. Manore, Grace L. Wong, et al.
Cells (2020) Vol. 9, Iss. 9, pp. 2114-2114
Open Access | Times Cited: 149
Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances
Prajwal Dhokne, Akash P. Sakla, Nagula Shankaraiah
European Journal of Medicinal Chemistry (2021) Vol. 216, pp. 113334-113334
Closed Access | Times Cited: 86
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts
Zhouling Xie, Shuzeng Hou, Xiaoxiao Yang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 9, pp. 6356-6389
Closed Access | Times Cited: 46
Development of pyrolo[2,3-c]pyrazole, pyrolo[2,3-d]pyrimidine and their bioisosteres as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological evaluation and molecular dynamics investigations
Eman M. Azmy, Mohamed Hagras, Menna A. Ewida, et al.
Bioorganic Chemistry (2023) Vol. 139, pp. 106729-106729
Closed Access | Times Cited: 31
Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy
Kenneth J. Pienta, Emma U. Hammarlund, Robert H. Austin, et al.
Seminars in Cancer Biology (2020) Vol. 81, pp. 145-159
Open Access | Times Cited: 65
Macrocyclic supramolecular biomaterials in anti-cancer therapeutics
Biki Hazarika, Ved Prakash Singh
Chinese Chemical Letters (2023) Vol. 34, Iss. 11, pp. 108220-108220
Closed Access | Times Cited: 20
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2
Joshua R. Hummel, Kai‐Jiong Xiao, Jeffrey Yang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 3112-3126
Closed Access | Times Cited: 6
Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights
Wagdy M. Eldehna, Raed M. Maklad, Hadia Almahli, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 1227-1240
Open Access | Times Cited: 24
A comprehensive analysis of the role of molecular docking in the development of anticancer agents against the cell cycle CDK enzyme
PRIYANKA SOLANKI, Nisarg Rana, Prakash C. Jha, et al.
Biocell (2023) Vol. 47, Iss. 4, pp. 707-729
Open Access | Times Cited: 16
Cyclin‐dependent kinases: Masters of the eukaryotic universe
Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, et al.
Wiley Interdisciplinary Reviews - RNA (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 14
Targeting cyclin‐dependent kinase 6 by vanillin inhibits proliferation of breast and lung cancer cells: Combined computational and biochemical studies
Mohd Yousuf, Anas Shamsi, Aarfa Queen, et al.
Journal of Cellular Biochemistry (2021) Vol. 122, Iss. 8, pp. 897-910
Closed Access | Times Cited: 32
Synthesis of novel indole-isoxazole hybrids and evaluation of their cytotoxic activities on hepatocellular carcinoma cell lines
Mohammed Hawash, Deniz Kahraman, Sezen Güntekin Ergün, et al.
BMC Chemistry (2021) Vol. 15, Iss. 1
Open Access | Times Cited: 32
Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline
Deendyal Bhurta, Sandip B. Bharate
Medicinal Research Reviews (2021) Vol. 42, Iss. 2, pp. 654-709
Closed Access | Times Cited: 31
Development of CDK4/6 Inhibitors: A Five Years Update
Alessandra Ammazzalorso, Mariangela Agamennone, Barbara De Filippis, et al.
Molecules (2021) Vol. 26, Iss. 5, pp. 1488-1488
Open Access | Times Cited: 30
Green synthesis, structural analysis and anticancer activity of dihydropyrimidinone derivatives
Jayanta Dowarah, Devanshi Patel, Brilliant N. Marak, et al.
RSC Advances (2021) Vol. 11, Iss. 57, pp. 35737-35753
Open Access | Times Cited: 30
Spiroisatin pyranopyrimide derivatives as receptor tyrosine kinase inhibitors and targeted anticancer agents
Alireza Alipour, Paria Farhadi, Kourosh Mobaraki, et al.
Journal of Molecular Structure (2025), pp. 141576-141576
Closed Access
CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients
Dan Wang, Yanhong Zhou, Hua Li, et al.
International Journal of General Medicine (2022) Vol. Volume 15, pp. 2233-2245
Open Access | Times Cited: 16
Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors
Mohammed Hawash
Cells (2024) Vol. 13, Iss. 19, pp. 1656-1656
Open Access | Times Cited: 3
A patent review of anticancer CDK2 inhibitors (2017–present)
Mohamed A. Said, Mohamed A. Abdelrahman, Mohammed A. S. Abourehab, et al.
Expert Opinion on Therapeutic Patents (2022) Vol. 32, Iss. 8, pp. 885-898
Closed Access | Times Cited: 15
Advanced approaches of developing targeted covalent drugs
Conghao Gai, Suzannah J. Harnor, Shihao Zhang, et al.
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 12, pp. 1460-1475
Open Access | Times Cited: 14
Design, synthesis, and biological evaluation of N-(pyridin-3-yl)pyrimidin-4-amine analogues as novel cyclin-dependent kinase 2 inhibitors for cancer therapy
Wenbin Zeng, Tangyang Ji, Yanting Zhang, et al.
Bioorganic Chemistry (2023) Vol. 143, pp. 107019-107019
Closed Access | Times Cited: 8
Discovery of New Coumarin-Based Lead with Potential Anticancer, CDK4 Inhibition and Selective Radiotheranostic Effect: Synthesis, 2D & 3D QSAR, Molecular Dynamics, In Vitro Cytotoxicity, Radioiodination, and Biodistribution Studies
Mona O. Sarhan, Somaia S. Abd El‐Karim, Manal M. Anwar, et al.
Molecules (2021) Vol. 26, Iss. 8, pp. 2273-2273
Open Access | Times Cited: 18
In Silico Analysis of Novel Bacterial Metabolites with Anticancer Activities
Pfariso Maumela, Mahloro Hope Serepa‐Dlamini
Metabolites (2024) Vol. 14, Iss. 3, pp. 163-163
Open Access | Times Cited: 2
Potential drug development and therapeutic approaches for clinical intervention in COVID-19
Jayanta Dowarah, Brilliant N. Marak, Umesh C. S. Yadav, et al.
Bioorganic Chemistry (2021) Vol. 114, pp. 105016-105016
Open Access | Times Cited: 15
Novel CDK2 Inhibitors for Treating Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2020) Vol. 11, Iss. 12, pp. 2346-2347
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top